Medicenna Therapeutics (TSE:MDNA) Hits New 1-Year Low – Time to Sell?

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.37 and last traded at C$0.39, with a volume of 65380 shares. The stock had previously closed at C$0.40.

Medicenna Therapeutics Stock Down 2.5%

The company has a 50-day moving average price of C$0.48 and a 200 day moving average price of C$0.70. The firm has a market capitalization of C$35.54 million, a PE ratio of -1.75 and a beta of 2.96. The company has a debt-to-equity ratio of 4.79, a current ratio of 1.52 and a quick ratio of 4.65.

Medicenna Therapeutics (TSE:MDNA) last released its earnings results on Thursday, June 25th. The company reported C($0.05) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. Analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.